Lung Cancer News From Medical News Today
Mon, 15 Mar 2010 00:16:33 +0100
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC)...
Sun, 14 Mar 2010 00:00:00 PDT
Stimuvax Will Become Decision Resources' Proprietary Clinical Gold Standard For The Treatment Of Locally Advanced Non-Small-Cell Lung Cancer
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Merck KGaA/Oncothyreon's Stimuvax vaccine earns Decision Resources' proprietary clinical gold standard status in 2013 and 2018 for the treatment of locally advanced non-small-cell lung cancer...
Sat, 13 Mar 2010 02:00:00 PDT
Genetic Variant Greatly Increases Lung Cancer Risk For Light Smokers
Individuals with a certain type of genetic susceptibility to lung cancer face a greatly increased risk for the deadly disease with even a small exposure to cigarette smoke, a study team that includes researchers from the University of Cincinnati (UC) has concluded...
Wed, 10 Mar 2010 04:00:00 PDT
News From The Journal Of Clinical Investigation: March 8, 2010
Warning sign for potential anticancer approach One treatment being investigated as an adjuvant for anticancer immunotherapies is the use of molecules that trigger the proteins TLR7 and TLR8. For example, the TLR7 stimulant imiquimod is used for the treatment of skin cancer and metastatic melanoma...
Tue, 09 Mar 2010 03:00:00 PDT
2nd European Lung Cancer Conference
Rapid advances in drug development, genetics and multidisciplinary treatment have brought the field of oncology to a critical moment, says Dr. Rafael Rosell from the Catalan Institute of Oncology in Badalona, Spain, co-chair of the second European Lung Cancer Conference (ELCC), which will be held in Geneva, Switzerland from 28 April to 1 May 2010...
Fri, 05 Mar 2010 06:00:00 PDT
Prolonged Use Of HRT Increases Incidence Of Lung Cancer By About 50 Percent: New Study
Women aged 50 to 76 who take estrogen plus progestin may have an increased risk of lung cancer, according to a new study published in the pre-print online edition of the Journal of Clinical Oncology...
Fri, 05 Mar 2010 01:00:00 PDT
The Effects Of Patient Attitudes On Patient Outcomes
Research published in the March edition of the Journal of Thoracic Oncology (JTO) explored the importance of a patient's outlook as it relates to health behavior and health status. Researchers focused on lung cancer patients and discovered that those who exhibited an optimistic disposition experienced more favorable outcomes than those with a pessimistic disposition...
Fri, 05 Mar 2010 00:00:00 PDT
'Salvage' Therapy Just As Suitable For NSCLC Patients Over Age 70 As For Younger Patients
Research published in the March issue of the Journal of Thoracic Oncology sought to determine whether differences existed in tolerance and efficacy between patients age 70 and over and younger patients with non-small cell lung cancer (NSCLC) receiving salvage targeted therapy with epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) or chemotherapy...
Fri, 05 Mar 2010 00:00:00 PDT
Synta Presents STA-9090 NSCLC Data At The IASLC 10th Annual Targeted Therapies Of The Treatment Of Lung Cancer Meeting
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I...
Tue, 02 Mar 2010 10:00:00 PDT
Novelos Therapeutics Pivotal Phase 3 Lung Cancer Trial Does Not Meet The Primary Survival Endpoint
Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos' pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy...
Fri, 26 Feb 2010 02:00:00 PDT
|
